Clinical trials
Sexually Transmitted Infections (Not HIV or Hepatitis) clinical trials
Below are recruiting sexually transmitted infections (not hiv or hepatitis) clinical trials, each written for real people, not researchers. We’re tracking 794 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06406634RecruitingPhase 2
Cadonilimab, Lenvatinib, and HAIC for Unresectable Liver Cancer
This trial tests a combination of three treatments for advanced liver cancer that can't be removed by surgery. It uses an immunotherapy drug (cadonilimab), a targeted therapy pill (lenvatinib), and a direct chemotherapy infusion into the liver (HAIC). The goal is to see if this combo can shrink tumors and improve outcomes.
Changsha, HunanAges 18–75 - NCT06420440RecruitingPhase 2
Pre-surgery treatment for liver cancer at high risk of return
This study tests a treatment given before surgery for liver cancer that is at high risk of coming back. You would receive a combination of chemotherapy directly into the liver artery (HAIC), a targeted pill (lenvatinib), and an immunotherapy drug (a PD-1 inhibitor) — if a computer model predicts you might benefit.
Xiangyang, HubeiAges 18–75 - NCT06426992Recruiting
Microwave ablation for small liver tumors
This study tests a microwave ablation device to destroy small liver tumors (up to 4 cm) using heat, without major surgery. It is designed for patients with limited disease (1 or 2 tumors) and good liver function.
SeoulAges 20–85 - NCT06431919Recruiting
Adding statin to carvedilol for cirrhosis with heart problems
This trial tests whether adding a statin (simvastatin) to the usual heart medication carvedilol helps people with both cirrhosis and a related heart problem live longer and avoid serious liver complications.
ChandigarhAges 18–65 - NCT06449339RecruitingPhase 4
Beta-blocker study for early-stage liver scarring
This study tests a medicine called carvedilol (a non-selective beta-blocker) to see if it can prevent complications in people with advanced chronic liver disease who are at high risk but haven't had serious problems like bleeding yet.
Hong KongAges 18 years+ - NCT06449833RecruitingPhase 4
Henagliflozin for liver fat in diabetes and fatty liver
This study tests whether a medicine called henagliflozin can help reduce fat in the liver for people with type 2 diabetes and non-alcoholic fatty liver disease. It may help improve liver health and blood sugar control at the same time.
Guangzhou, GuangdongAges 18–75 - NCT06455280RecruitingPhase 1
A study of Siplizumab for autoimmune liver disease patients awaiting transplant
This trial tests a drug called Siplizumab in people with autoimmune hepatitis or primary sclerosing cholangitis who are on the liver transplant waitlist. It aims to see if the drug can help manage their condition before and after transplant.
New York, New YorkAges 18 years+ - NCT06457477Recruiting
PD-1 antibody and peginterferon for chronic hepatitis B
This trial tests a combination of a PD-1 antibody (a type of immunotherapy) and peginterferon alpha for people with chronic hepatitis B whose virus is already under control but whose surface antigen levels haven't improved much with standard therapy. It aims to see if the combo can help reduce the hepatitis B surface antigen further.
Beijing, Beijing MunicipalityAges 18–65 - NCT06484530RecruitingPhase 4
Gene-guided NAC to prevent TB drug liver injury
This trial tests whether a medicine called N-acetylcysteine (NAC) can help prevent liver damage caused by standard TB drugs. If you have a higher risk of liver injury based on your genes, you may be given NAC along with your TB treatment.
Bangkok Noi, BangkokAges 18–80 - NCT07317011Recruiting
Active referral for hepatitis B patients
This trial aims to connect adults with chronic hepatitis B to proper care. It tests an active referral program for patients hospitalized in specific departments in Bergamo, Italy, or attending certain clinics, to see if it improves follow-up and treatment.
BergamoAges 18–100 - NCT06492408RecruitingPhase 2
Immunotherapy before surgery for liver cancer
This trial tests giving two immunotherapy drugs directly into the tumor before surgery for liver cancer. It aims to see if this approach can shrink the tumor and improve outcomes for patients who are candidates for surgery.
Guanzhou, GuangdongAges 18–75 - NCT06515314RecruitingPhase 1
TCR-T cell therapy for AFP-positive liver and other cancers
This trial tests an experimental cell treatment called HRYZ-T102 TCR-T for people with advanced liver cancer or other solid tumors that make a protein called AFP. The treatment uses your own immune cells, modified in a lab to target and kill cancer cells.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06519162Recruiting
Liver-gut link study for liver disease patients and their families
This study looks at how gut bacteria differ in people with specific liver diseases and their household contacts. It may help researchers understand the connection between the liver and gut.
Daejeon, Jung-guAges 19 years+ - NCT06519578Recruiting
Liver Cancer Study: Comparing Two Chemotherapy Drugs via Artery Infusion
This study compares two chemotherapy drugs (raltitrexed and 5-fluorouracil) given directly into the liver's main artery to treat liver cancer. It aims to see which drug works better and is safer for people with hepatocellular carcinoma.
ShanghaiAges 18–75 - NCT06538480RecruitingPhase 4
Zopa retreatment study for recurrent respiratory papillomatosis
This trial tests if people with recurrent respiratory papillomatosis (growths in the airway caused by HPV) can safely get more doses of the study drug Zopa and checks if the virus spreads after treatment. It may help people who have already tried Zopa or are considering it for the first time.
Atlanta, GeorgiaAges 18 years+ - NCT06541067RecruitingPhase 2
Posaconazole to prevent fungal infections after stem cell transplant
This trial tests whether the antifungal drug posaconazole can prevent serious fungal infections in people who are at high risk after a stem cell transplant. If you qualify, you would take posaconazole during your recovery.
Nantes, FranceAges 18 years+ - NCT06550622Recruiting
Better Detection of Hepatitis B Virus After Treatment
This study looks at a new way to detect the hepatitis B virus in the blood, even after standard tests say it's gone. It may help people who have stopped treatment and want to see if the virus comes back.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT06568484RecruitingPhase 2/Phase 3
Preventing TB with bedaquiline in people exposed to TB
This study tests if bedaquiline can prevent tuberculosis (TB) in people who have been in close contact with someone with active TB, including people living with HIV. If you qualify, you would take the study medicine and be monitored to see if it prevents you from developing TB.
LimaAges Any age - NCT06576934Recruiting
Early TIPS for liver cirrhosis with ascites
This study tests whether placing a small tube (called a TIPS) early in the liver can help people with cirrhosis who have their first episode of moderate to severe belly fluid buildup. The goal is to see if this early procedure improves outcomes compared to standard care.
Freiburg im BreisgauAges 18–80 - NCT06582654Recruiting
Antibody detection in first-void urine
This study looks at a new way to detect HPV antibodies in a urine sample. It is for people who have received the HPV vaccine to help improve testing.
Edegem, AntwerpAges 9–70 - NCT06585020RecruitingPhase 2
Inhaled antibiotic for Mycobacterium xenopi lung infection
This trial tests an inhaled antibiotic (amikacin liposome) for people with a lung infection caused by a germ called Mycobacterium xenopi. The goal is to see if this treatment can help fight the infection with fewer side effects.
AmiensAges 18 years+ - NCT06599918RecruitingPhase 2
Nicotinamide for liver scarring in fatty liver disease
This study tests whether nicotinamide (a form of vitamin B3) can help reduce liver scarring in people with nonalcoholic fatty liver disease. You may qualify if you have moderate to severe liver scarring and are between 18 and 85 years old.
BarcelonaAges 18–85 - NCT07459309Recruiting
Combination treatment for liver cancer for people who can't have surgery
This trial tests a new combination treatment that uses heat (ablation) and other therapies to destroy liver tumors. It's for people who cannot have surgery or choose not to, and whose tumor is a specific size.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06608199RecruitingPhase 3
Pneumonia vaccine study for healthy infants
This study tests a new pneumonia vaccine (PCV13) in healthy infants to see if it works as well as a current vaccine. It compares the immune response and safety of the two vaccines.
Denpasar, BaliAges 1 month–2 months
Hear when a new Sexually Transmitted Infections (Not HIV or Hepatitis) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for sexually transmitted infections (not hiv or hepatitis)?
- Yes. Clin2 currently lists 794 recruiting sexually transmitted infections (not hiv or hepatitis) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a sexually transmitted infections (not hiv or hepatitis) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a sexually transmitted infections (not hiv or hepatitis) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.